Serum SH3BP5-specific Antibody Level is a Biomarker of AtherosclerosisHiwasa T1*,Tomiyoshi G1,2, Nakamura R1,2, Shinmen N1,2, Kuroda H2, Kunimatsu M3, Mine S4,5,6, Machida T6, Sato E7, Takemoto M8, Hattori A8, Kobayashi K8, Kawamura H8, Ishibashi R8, Yokote K8, Kitamura K9, Ohno M10,11, Chen PM10, Nishi E10,11, Ono K10, Kimura T10, Takizawa H12, Kashiwado K13, Kamitsukasa I14,15, Wada T16, Aotsuka A16, Sunami K17, Kobayashi E4, Yoshida Y4, Matsutani T4, Iwadate Y4, Mori M18, Uzawa A18, Muto M18, Sugimoto K1,18, Kuwabara S18, Iwata Y19,20, Kobayashi Y19, Terada J21, Matsumura T21, Sakao S21, Tatsumi K21, Ito M22, Shimada H22, Zhang XM1, Kimura R1, Wang H1,23, Iwase1 K, Ashino H1, Taira A1, Arita E1, Goto K1, Kudo T24 and Doi H24
- *Corresponding Author:
- Takaki Hiwasa
Department of Biochemistry and Genetics
Graduate School of Medicine
Chiba University, Inohana 1-8-1
Chuo-ku, Chiba 260- 8670, Japan
Tel: +81 432262541
E-mail; [email protected]
Received Date: April 04, 2016; Accepted Date: April 25, 2017; Published Date: May 01, 2017
Citation: Hiwasa T, Tomiyoshi G, Nakamura R, Shinmen N, Kuroda H, et al. (2017) Serum SH3BP5-specific Antibody Level is a Biomarker of Atherosclerosis. Immunome Res 13:132. doi: 10.4172/17457580.1000132
Copyright: © 2017 Hiwasa T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract Background: The discovery and development of novel biomarkers that could facilitate early diagnosis and thus prevent the progression of atherosclerosis-related diabetes mellitus (DM), cerebral infarction (CI), and cardiovascular disease (CVD) has garnered much research interest. Notably, recent reports have described a number of highly sensitive antibody markers. In this study, we aimed to identify additional antibody markers that would facilitate screening. Methods: The amplified luminescent proximity homogeneous assay (AlphaLISA) method, which incorporates glutathione- or streptavidin-donor beads and anti-human-IgG-acceptor beads, was used to evaluate serum antibody levels in serum samples. The protein array method was used for the initial screening, and peptide arrays were used to identify epitope sites. Results: The protein array identified SH3 domain-binding protein 5 (SH3BP5) as a target antigen of serum IgG antibodies in the sera of patients with atherosclerosis. We prepared recombinant glutathione S-transferase (GST)- fused SH3BP5 protein. Peptide arrays revealed that the epitope site recognized by serum antibodies is located within amino acids 161–174 of SH3BP5. AlphaLISA revealed significantly higher serum antibody levels against both the SH3BP5 protein and peptide in patients with DM, acute-phase CI, transient ischemic attack, CVD or chronic kidney disease (CKD), than in healthy donors. Furthermore, areas under the receiver operating characteristic curves of these antibodies were higher in patients with CKD and DM than in other patients. Spearman correlation analysis revealed associations between the serum antibody levels against SH3BP5 peptide and artery stenosis, hypertension, and smoking. Conclusions: The serum anti-SH3BP5 antibody marker appears to be useful for estimating the progress of atherosclerosis and may discriminate atherosclerosis associated with hypertension and/or habitual smoking.